Trinh Van Anh, Joseph Jocelyn, Hwu Wen-Jen
Division of Pharmacy, Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Discov Med. 2018 Jan;25(135):31-40.
Since their approval by regulatory agencies worldwide, the anti-PD-1 monoclonal antibodies (mAbs), as monotherapy or in combination with ipilimumab, have become the standard frontline therapy for advanced BRAF-wild-type melanoma and an eminent rival to targeted therapy in the first-line setting for unresectable BRAF-mutated melanoma. Mature survival data from randomized phase 3 trials have emerged, confirming their position in the current treatment schema for advanced melanoma. Recently, the clinical utility of anti-PD-1 agents has extended into other disease settings, such as resected high-risk melanomas, non-cutaneous subtypes, and brain metastases. How to best combat resistance to anti-PD-1 mAbs remains the major focus of clinical investigations. This review aims to provide an update on the recent progress and current challenges relating to the clinical application of anti-PD-1 agents in the treatment of advanced melanoma.
自全球监管机构批准以来，抗程序性死亡蛋白1（PD-1）单克隆抗体（mAb）作为单一疗法或与伊匹单抗联合使用，已成为晚期BRAF野生型黑色素瘤的标准一线治疗方法，并且在不可切除的BRAF突变黑色素瘤的一线治疗中成为靶向治疗的有力竞争对手。来自随机3期试验的成熟生存数据已经出现，证实了它们在晚期黑色素瘤当前治疗方案中的地位。最近，抗PD-1药物的临床应用已扩展到其他疾病领域，如切除的高危黑色素瘤、非皮肤亚型和脑转移瘤。如何最好地对抗抗PD-1 mAb的耐药性仍然是临床研究的主要焦点。本综述旨在提供有关抗PD-1药物在晚期黑色素瘤治疗中临床应用的最新进展和当前挑战的最新信息。
